Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2304MR)

This product GTTS-WQ2304MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2304MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6690MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ14477MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ11124MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ7613MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ1516MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ2469MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ4031MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ3692MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW